Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

TEVA Teva Pharmaceutical Industries Ltd

22,0201

0,7101 (3,33%)

21 Dez 2024 - Geschlossen

Verzögert um 15 Minuten

Form 144/A - Report of proposed sale of securities: [Amend]

Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Click Here for more Teva Pharmaceutical Indu... Charts.

Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
Von Dez 2023 bis Dez 2024

Click Here for more Teva Pharmaceutical Indu... Charts.

News Teva Pharmaceutical Industries Ltd

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
Freitag 20 Dezember 2024 (14 Stunden vor) • GlobeNewswire Inc.

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
Dienstag 17 Dezember 2024 (4 Tage vor) • GlobeNewswire Inc.

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
Mittwoch 11 Dezember 2024 (1 Woche vor) • GlobeNewswire Inc.

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
Freitag 6 Dezember 2024 (2 Wochen vor) • GlobeNewswire Inc.

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
Mittwoch 4 Dezember 2024 (2 Wochen vor) • GlobeNewswire Inc.

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
Dienstag 26 November 2024 (4 Wochen vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 21 November 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 20 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Teva to Present at the Jefferies London Healthcare Conference
Freitag 8 November 2024 (1 Monat vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 6 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 6 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
Mittwoch 6 November 2024 (1 Monat vor) • GlobeNewswire Inc.

Weitere Teva Pharmaceutical Industries Ltd News-Artikel

Gold vs US Dollar

Financial Select Sector

Energy Select Sector SPDR

Deutsche Telekom

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen